Key result
A drug-free bioresorbable scaffold resulted in similar late lumen loss compared to a bare metal stent at 6 months in porcine coronary arteries (P=0.68).
Why the study?
Does a drug-free bioresorbable scaffold improve late lumen loss compared to a bare metal stent in porcine coronary arteries?
Does a drug-free bioresorbable scaffold improve late lumen loss compared to a bare metal stent in porcine coronary arteries?
p-value: p=0.68
A novel drug-free bioresorbable scaffold demonstrated similar 6-month outcomes to a bare metal stent in a porcine model, with evidence of early dismantling and late lumen enlargement.
Similar performance in porcine arteries does not inform clinical use; leaves open whether drug-free scaffolds confer advantages in humans.
BACKGROUND: We aimed to evaluate a new drug-free fully bioresorbable lactic acid-based scaffold designed to allow early dismantling synchronized with artery wall healing in comparison with a bare metal stent (BMS). METHODS AND RESULTS: Twenty-three BMS (3.0×12 mm) and 36 lactic acid-based bioresorbable scaffolds (BRS, 3.0×11 mm) were implanted in porcine coronary arteries. QCA and optical coherence tomographic analyses were performed immediately after implantation and repeated after 1, 3, and 6 months. Microcomputed tomography was used to detect scaffold dismantling. Polymer degradation was evaluated throughout the study. The primary end-point was late lumen loss, and the secondary end-points were scaffold/stent diameter and acute recoil. Acute recoil was low and comparable between the BRS and the BMS groups (4.6±6.7 versus 4.6±5.1%; P=0.98). BRS outer diameter increased significantly from 1 to 6 months indicating late positive scaffold remodeling (P<0.0001), whereas BMS diameter remained constant (P=0.159). Late lumen loss decreased significantly from 1 to 6 months in the BRS group (P=0.003) without significant difference between BRS and BMS groups at 6 months (P=0.68). Microcomputed tomography identified BRS dismantling starting at 3 months, and weight-average molar masses of scaffold parts were 20% and 14% of their initial values at 3 and 6 months. CONCLUSIONS: BRS and BMS have similar 6-month outcomes in porcine coronary arteries. Interestingly, BRS dismantling was detected from 3 months and resulted in late lumen enlargement by increased scaffold diameter at 6 months.
No takes yet. Share an insight, caveat, or question.
Durand et al. (2013) studied Porcine coronary arteries (n=59). Drug-free fully bioresorbable lactic acid-based scaffold (BRS) vs. Bare metal stent (BMS) was evaluated on Late lumen loss (p=0.68). A drug-free bioresorbable scaffold resulted in similar late lumen loss compared to a bare metal stent at 6 months in porcine coronary arteries (P=0.68).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: